Renwick Goldberg, MD
Hematology & Oncology · Myrtle Beach, SCNPI 1679566178
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in SC, where the typical reported total is $4,020.
Across 67 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$266
- E.r. Squibb & Sons, L.L.C.$230
- Jazz Pharmaceuticals Inc.$134
- AbbVie$86
- Merck$81
- Gilead$57
- plus $387 from 16 others
Across 5 payments — averaging $2190.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$11K
What the payments were for
- Food & beverage$1,19296%
- Education$494%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $266 |
| E.r. Squibb & Sons, L.L.C. | 14 | $230 |
| Jazz Pharmaceuticals Inc. | 7 | $134 |
| AbbVie | 5 | $86 |
| Merck | 4 | $81 |
| Gilead(2 entities) | 4 | $57 |
| Johnson & Johnson | 2 | $55 |
| Pfizer | 2 | $40 |
| GSK | 2 | $34 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $31 |
| Seagen Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Bristol Myers Squibb | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Sobi, Inc | 1 | $19 |
| Genentech USA, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Deciphera Pharmaceuticals Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $13 |
How this compares
$1,240 in reported general payments places this provider in the 20th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 74 | $1,099,675 |
| Lenalidomide | 45 | $597,198 |
| PomalystPomalidomide | 24 | $569,664 |
| XtandiEnzalutamide | 30 | $415,163 |
| RevlimidLenalidomide | 20 | $386,304 |
| ImbruvicaIbrutinib | 13 | $212,772 |
| IbrancePalbociclib | 12 | $190,221 |
| NubeqaDarolutamide | 12 | $153,119 |
| Imatinib Mesylate | 25 | $118,349 |
| VenclextaVenetoclax | 25 | $65,119 |
| XareltoRivaroxaban | 31 | $22,112 |
| OxycontinOxycodone Hcl | 14 | $17,208 |
| Deferasirox | 11 | $8,569 |
| Fentanyl | 54 | $8,328 |
| Exemestane | 21 | $3,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $230 | $569,66424 claims |
| Bristol Myers SquibbRevlimid | $21 | $386,30420 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $31 | $212,77213 claims |
| PfizerIbrance | $40 | $190,22112 claims |
| AbbVieVenclexta | $86 | $65,11925 claims |
| Johnson & JohnsonXarelto | $55 | $22,11231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Myrtle Beach
- Emily TouloukianMyrtle Beach$20K
- Suzanne FanningGreenville$927K
- Vikas DemblaSpartanburg$568K
- Stephen DyarGreenville$413K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
- Bhumika PatelGreenville$225K
- Ming LimCharleston$94K
- George GeilsCharleston$76K
- Joe StephensonGreenville$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.